89zr-pembrolizumab - a radioimmunoconjugate composed of pembrolizumab, a humanized monoclonal antibody immunoglobulin (ig) g4 antibody directed against the human cell surface receptor programmed cell death 1 (pd-1; pdcd1; cd279; programmed cell death-1), labeled with the radioisotope zirconium zr 89, with potential use as an imaging agent upon positron emission tomography (pet). Upon administration of zirconium zr 89 pembrolizumab, the antibody moiety binds to pd-1, an inhibitory signaling receptor expressed on the surface of activated t-cells, and blocks the binding to and activation of pd-1 by its ligands. Upon pet imaging, pd-1-expressing t-cells, as well as pembrolizumab biodistribution, can be visualized and the expected response to treatment with pembrolizumab, as well as selection of patients that would respond to pembrolizumab, can be assessed. The ligands for pd-1 include programmed cell death-1 ligand 1 (pd-l1), which is overexpressed on certain cancer cells, and programmed cell death-1 ligand 2 (pd-l2), which is primarily expressed on antigen-presenting cells (apcs). Activated pd-1 negatively regulates t-cell activation and plays a key role in tumor evasion from host immunity.
Up to date info
Latest research - 89zr-pembrolizumab
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 89zr-pembrolizumab for any updates.